RemeGen (REGMF) Stock Price, News & Analysis

Company Overview

RemeGen is a China-based biopharmaceutical company focused on discovering, developing and commercializing innovative biologic therapies. The company’s research programs primarily target autoimmune diseases, oncology and other serious medical conditions, with an emphasis on antibody-based medicines and antibody-drug conjugates.

RemeGen’s principal products include telitacicept, a recombinant fusion protein designed to inhibit the activity of B-cell activating factor and a proliferation-inducing ligand, and disitamab vedotin, an antibody-drug conjugate that targets HER2-positive tumors. Telitacicept has received regulatory approval in China for autoimmune disease treatment, while disitamab vedotin has been approved in China for certain HER2-expressing cancers. The company also maintains a pipeline of investigational therapies in areas including ophthalmology, immunology and oncology.

Founded in 2012, RemeGen is headquartered in Yantai, Shandong Province, China. Its commercial operations are centered in China, while the company pursues international development and partnering opportunities for selected products and drug candidates. RemeGen is publicly listed in Hong Kong, and its shares also trade over the counter in the United States under the symbol REGMF.

Key Stats

• Today's Range: $9.96 to $9.96
• 50-Day Range: $9.54 to $11.49
• 52-Week Range: $9.50 to $15.91
• Volume: N/A
• Average Volume: 917 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/11/2026
• Next Earnings (Estimated): 10/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:REGMF
• CIK: N/A
• Web: www.remegen.com
• Phone: 86-53-56357-3672
• Fax: N/A
• Employees: 3,048
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A